Table 1

Clinical data, effective dose, activity:dose ratio, and response rates in [90Y]-labeled DOTATOC-treated glioma patients

PatientAge, genderHistologya locationPrevious therapyKPSbAutoradiographycActivity (fractions) (MBq)Volume (ml)Effective dose (Gy)Activity: dose ratio (MBq/Gy)ResponsedProgression-free/Overall survivale
Low-grade gliomas (WHO grade II)
TH30, McAII-RfB-Dr-R*90ND370 (2)20100 ± 203.7CR+4/+4
THi31, MAII-RfS90NA555 (1)15380 ± 751.5SD+15/+15
CM43, FOII-BfB100ND2405 (4)36550 ± 1104.4SD18/18f
BS30, MOII-RfS100++555 (1)12208 ± 212.7SD+14/+14
AB42, FAII-LfB-R100ND1100 (2)30280 ± 403.9SD+6/+6
BF39, MAII-LfB-R60ND740 (3)3060 ± 1512.3sDet0/8
NJ43, MAII-LftB-R502200 (3)7999 ± 2422.2sDet0/13
Anaplastic gliomas (WHO III-IV)
FR63, FOIII-RfpS100++1110 (2)20480 ± 552.3SD+10/+10
WH43, MGBM-RtoS-R100+++3330 (3)130335 ± 409.8sDet0/6
SI37, FGBM-LtS-R802405 (4)77496 ± 1004.8SD10/15
WP28, MGBM-RtoS-R-C90ND2035 (3)47147 ± 3013.8sDet0/9
  • a c, cystic; AII, fibrillary astrocytoma; OII, oligodendroglioma grade II; AIII, anaplastic astrocytoma; GBM, glioblastoma multiforme; R, right; L, left; f, frontal; t, temporal; o, occipital; B, biopsy; R*, brachytherapy with 125I seeds; Dr, cyst drainage; R, external beam radiotherapy; S, surgery; C, chemotherapy.

  • b Karnofsky score at time of enrollment.

  • c ND, not done; NA, not assessable due to strong gliosis; +, SR-positive; −, SR-negative.

  • d CR, complete remission of a cyst in cystic AII; SD, stable disease = no progression on MRI and clinically stable for progression-free survival period as defined by a stable KPS and no signs of progression on MRI; PD, progressive disease; sDet, slow deterioration due to disease progression and possibly radionecrosis.

  • e Survival in months.

  • f Untreated epileptic status.